**CURRICULUM VITAE**

**Michael Oscar Koch, M.D.**

**OFFICE ADDRESS:**

Department of Urology

535 North Barnhill Drive, Suite 150

Indiana University School of Medicine

Indianapolis, Indiana 46202-5289

317-944-7338

**CITIZENSHIP:**

U.S. Citizen

**EDUCATION:**

1977 A.B., Dartmouth College

Hanover, New Hampshire

1981 M.D., Dartmouth Medical School

Hanover, New Hampshire

**HONORS:**

Distinction in Engineering Major, Dartmouth College, 1977

Cum Laude, Dartmouth College, 1977

Alpha Omega Alpha Honor Medical Society, Dartmouth Medical School, 1981

Honorable Mention, American Urological Association Sponsored Essay Contest in Laboratory Research, 1985

Member of European Association of Urology - American Urological Association Exchange Program, 1996

Elected to American Association of Genitourinary Surgeons, 2004

Named the John P. Donohue Professor of Urology, 2008

Elected to the Clinical Society of Genitourinary Surgeons, 2009 (75 US members)

Elected to the Clinical Society, 2009 (25 US members)

Awarded the Distinguished Contribution Award from the American Urological Association, 2015

**LICENSURE:**

Tennessee #MD 17568 (Retired), October 20, 1986

Indiana, April 29, 1998

**BOARD CERTIFICATION:**

National Board of Medical Examiners, 1982

American Board of Urology, 1989

Recertification American Board of Urology, 1996, 2008

**POSTGRADUATE MEDICAL TRAINING:**

1981 **-** 1982 Internship, General Surgery

Dartmouth-Hitchcock Medical Center

Hanover, New Hampshire

1982 **-** 1983 Residency, General Surgery

Dartmouth-Hitchcock Medical Center

Hanover, New Hampshire

1983 **-** 1984 Surgical Research Fellowship

Dartmouth Medical School

Hanover, New Hampshire

1984 **-** 1986 Residency, Urology

Vanderbilt University Medical Center

Nashville, Tennessee

1986 **-** 1987 Chief Residency, Urology

Vanderbilt University Medical Center

Nashville, Tennessee

**FACULTY APPOINTMENTS:**

1987 **-** 1991 Assistant Professor

Department of Urology

Vanderbilt University School of Medicine

Nashville, Tennessee

1991 **-** 1992 Interim Chairman

Department of Urology

Vanderbilt University School of Medicine

Nashville, Tennessee

**FACULTY APPOINTMENTS CONTINUED:**

1992 **-** 1998 Associate Professor

Department of Urologic Surgery

Vanderbilt University School of Medicine

Nashville, Tennessee

1995 **-** 1998 Vice Chairman

Department of Urologic Surgery

Vanderbilt University School of Medicine

Nashville, Tennessee

1998 **-** Present Professor and Chairman

Department of Urology

Indiana University School of Medicine

Indianapolis, Indiana

**HOSPITAL APPOINTMENTS:**

1987 **-** 1998 Chief of Urology, Department of Veterans Affairs Medical Center, Nashville, Tennessee

1998 **-** Present Active Staff at Roudebush Veterans Administration Medical Center, Indiana University Heath System, and Wishard Memorial Hospital, Indianapolis, Indiana and IU Health University and Methodist

1998**-** Present Chairman, Department of Urology, Indiana University Medical Center

**PROFESSIONAL SOCIETIES:**

American Board of Urology

American College of Surgeons

American Medical Association

American Urological Association

North Central Section of the American Urological Association

American Urological Association/AFUD Research Committee

Indiana State Medical Association

Vanderbilt Urology Society

Society of University Urologists

Society of Urologic Oncology

Society of Clinical Urologists

Society for Basic Urologic Research

Societe Internationale d'Urologie

European Association of Urology

American Society of Clinical Oncology

**RESEARCH GRANTS:**

1988 **-** 1990 Veterans Administration Research Advisory Group, Metabolic Complications of Urinary Diversion Through Intestinal Segments, $60,500

1990 **-** 1993 Department of Veterans Affairs Medical Center, Merit Review Grant, Pathophysiology of Metabolic Alterations Following Urinary Diversion, $128,800

1993 **-** 1996 Department of Veterans Affairs Medical Center, Merit Review Grant, Mechanisms of Potassium and Ammonium Absorption in Intestine, $158,100.

1997 Gene Therapy Pilot Project, $35,000.

1997 **-** 1998 National Cancer Institute Cancer Center Support Grant, Progression of prostate cancer to androgen independence: a role for the androgen receptor, $15,000.

2001 **-** 2010 Selenium and Vitamin E Cancer Prevention trial (SWOG), $2,500,000/12 years-Principal investigator

**CLINICAL RESEARCH STUDIES:**

1. A Randomized Comparative Trial of Casodex vs. Flutamide Used in Combination with Medical Castration in Patients with Untreated Metastatic Prostate Cancer. Sponsor - Zeneca Pharmaceuticals Group. **MO Koch -** Principal Investigator**.**
2. Phase II Study of Oral Bropirimine in Adult Patients with BCG-Resistant Bladder Carcinoma in situ or with Bladder Carcinoma in situ and Intolerance to BCG. Sponsor - The Upjohn Company. **MO Koch -** Principal Investigator**.**
3. Protocol for Use of Oral Bropirimine in Named Adult Patients with Bladder Carcinoma. Sponsor - The Upjohn Company. **MO Koch -** Principal Investigator**.**
4. Phase III Study of Oral Bropirimine vs Intravesical BCG in Adult Patients with BCG - Native Bladder Carcinoma in situ. Sponsor-The Upjohn Company. **MO Koch -** Principal Investigator**.**
5. Bropirimine (U-54461S) Oral Tablets: Phase II Study in Adults with Extravesicle Carcinoma in situ (CIS) BCG - Resistant Bladder CIS or Bladder CIS and Intolerance to BCG. Sponsor - The Upjohn Company. **MO Koch -** Principal Investigator**.**
6. Multicenter Randomized Phase II/III Trial of CD8(+) Tumor Infiltrating Lymphocyte Cell Therapy and

Recombinant Interleukin-2 in Metastatic Renal Cell Cancer. Sponsor - Applied Immune Sciences. **MO Koch -** Principal Investigator**.**

1. A Double Blind, Parallel Group, Randomized Trial To Compare The Efficacy and Safety of Enoxaparin 40 mg SC QD and Unfractionated Heparin 5000 IU SC TID During 6-12 Days For Prevention of Deep Venous Thrombosis (DVT) in 800 Evaluable Patients After Planned Elective Curative Cancer Surgery. Sponsor - Rhone-Poulenc Rorer Pharmaceuticals. **MO Koch -** Principal Investigator**.**
2. Prostate Cancer Prevention Trial. Sponsor - National Cancer Institute, Division of Cancer Prevention and Control. **MO Koch -** Co-Principal Investigator**.**
3. D73P24: An Open Label, Non-Comparative Phase II Study of the Safety and Efficacy of Photodynamic Therapy (PDT) Utilizing PHOTOFRIN Polyporphyrin in the Treatment of Refractory Transitional Cell Carcinoma In Situ of the Urinary Bladder as an Alternative to Cystectomy. Sponsors - QLT Phototherapeutics, Inc and Lederle Laboratories. **MO Koch -** Co-Principal Investigator.
4. A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex) vs Placebo in Patients with Early Prostate Cancer. Sponsor - Zeneca Pharmaceuticals. **MO Koch -** Co-Principal Investigator.
5. Randomized Prospective Study Comparing Intermittent vs Continuous Androgen Deprivation with Lupron Depot in Clinical Stage D2 Prostate Cancer. Sponsor - TAP Holdings, Inc. **MO Koch -** Co-Principal Investigator.
6. A Phase III, Multi-Center Open-Label, Randomized Study of Abarelix-Depot vs Lupron Depot, in Patient with Prostate Cancer Who Are Candidates for Initial Hormonal Therapy. **MO Koch** **-** Principal Investigator.
7. A Multi-Center Study of Abarelix in Patients with Prostate Cancer in Whom GnRH Agonists are Contraindicated. **MO Koch** **-** Principal Investigator.
8. A Phase 3, Multicenter, Open-Label Randomized Study of Abarelix-Depot 100 mg. IM vs. Lupron Depot 7.5 mg IM in Patients Who are Candidates for Initial Hormonal Therapy. **MO Koch** **-** Principal Investigator.
9. Use of HIFU to treat Localized Prostate Cancer and Locally recurrent prostate cancer after radiation therapy or surgery. **MO Koch** **-** Principal Investigator. Focus surgery.
10. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy. **MO Koch** **-** Principal Investigator.
11. Selenium and Vitamin E Cancer Prevention Trial (SELECT). **MO Koch** **-** Principal Investigator.
12. A study to determine whether CCP scores can predict Progression to systemic disease and response to external beam radiation therapy. **MO Koch** **-** Principal Investigator.
13. A multicenter clinical study of the Sonablate® 500 (Sonablate) for the Treatment of locally Recurrent prostate cancer with HIFU (STAR Trial). **MO Koch** **-** Principal Investigator
14. A Phase 0 Single-center Clinical Study to Evaluate Biodistribution of 99mTc-EC0652 in Patients with Recurrent Prostate Cancer. **MO Koch** **-** Co-Principal Investigator.
15. A Randomized, Double Blind, Placebo Controlled Phase 3 Trial of Immunotherapy With Autologous Antigen Presenting Cells Loaded With PA2024 (Provenge, APC8015) in Asymptomatic Subjects With Gleason Sum Less than or Equal to 7, Metastatic, Androgen Independent Prostatic Adenocarcinomas. **MO Koch** **-** Co-Principal Investigator.
16. 14CL403: A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy. **MO Koch** **-** Principal Investigator.
17. A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma. **MO Koch** **-** Co-Principal Investigator.
18. A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent versus Sequential Administration of Abiraterone Acetate plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer. **MO Koch** **-** Co-Principal Investigator.
19. Randomized controlled trial examining the return of urinary continence after robot-assisted radical prostatectomy with or without a urethrovesical sling. **MO Koch** **-** Co-Principal Investigator.

**PUBLICATIONS:**

1. **Koch MO**, McDougal WS: Determination of renal function following urinary diversion through intestinal

segments. J Urol. 1985 Mar;133(3):517-20.

1. **Koch MO**, McDougal WS: Chlorpromazine: adjuvant therapy for the metabolic derangements created by

urinary diversion through intestinal segments. J Urol. 1985 Jul;134(1):165-9.

1. **Koch MO**, McDougal WS: Nicotinic acid: treatment for the hyperchloremic acidosis following urinary

diversion through intestinal segments. J Urol. 1985 Jul;134(1):162-4.

1. **Koch MO**, McDougal WS: The pathophysiology of hyperchloremic metabolic acidosis after urinary

diversion through intestinal segments. Surgery. 1985 Sep;98(3):561-70.

1. McDougal WS, **Koch MO**: Accurate determination of renal function in patients with intestinal urinary

diversions. J Urol. 1986 Jun;135(6):1175-8.

1. **Koch MO**, McDougal WS: Urologic causes of the acute abdomen. Surg Clin North Am. 1988

Apr;68(2):399-413.

1. McDougal WS, **Koch MO**, Shands C 3rd, Price RR: Bony demineralization following urinary intestinal

diversion. J Urol. 1988 Oct;140(4):853-5.

1. **Koch MO**, McDougal WS: Bone demineralization following ureterosigmoid anastomosis: an experimental

study in rats. J Urol. 1988 Oct;140(4):856-9. Erratum in: J Urol 1989 Jan;141(1):192.

1. **Koch MO**, McDougal WS: Penile carcinoma: the case for primary lymphadenectomy. Cancer Treat Res.

1989;46:55-64.

1. McDougal WS, **Koch MO:** [Effect of sulfate on calcium and magnesium homeostasis following urinary](http://www.ncbi.nlm.nih.gov/pubmed/2709657)

[diversion.](http://www.ncbi.nlm.nih.gov/pubmed/2709657) Kidney Int. 1989 Jan;35(1):105-15

1. McDougal WS, **Koch MO:** [Phallic reconstruction during exenterative surgery for invasive urethral](http://www.ncbi.nlm.nih.gov/pubmed/2709509)

[carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/2709509) J Urol. 1989 May;141(5):1201-3.

1. Erb RE, Kaufman AJ, **Koch MO**, Dutt KS, Burnett LS, Winfield AC: [Adenocarcinoma in a sigmoid](http://www.ncbi.nlm.nih.gov/pubmed/2173191)

[conduit: case report.](http://www.ncbi.nlm.nih.gov/pubmed/2173191) Urol Radiol. 1990;12(2):115-7

1. **Koch MO**, Gurevitch E, Hill DE, McDougal WS: [Urinary solute transport by intestinal segments: a](http://www.ncbi.nlm.nih.gov/pubmed/2342200)

[comparative study of ileum and colon in rats.](http://www.ncbi.nlm.nih.gov/pubmed/2342200) J Urol. 1990 Jun;143(6):1275-9.

1. Hill DE, McDougal WS, Stephens H, Fogo A, **Koch MO**: [Physiologic and pathologic alterations](http://www.ncbi.nlm.nih.gov/pubmed/2231958)

[associated with ultrasonically generated shock waves.](http://www.ncbi.nlm.nih.gov/pubmed/2231958) J Urol. 1990 Dec;144(6):1531-4.

1. Fleischer AC, Rao BK, **Koch MO**: [New developments in transrectal sonography of the prostate.](http://www.ncbi.nlm.nih.gov/pubmed/2282253) Curr Opin

Radiol. 1990 Dec;2(6):777-84.

1. Concepcion RS, **Koch MO**, McDougal WS, Stewart JR, Merrill WH: [Management of primary nonrenal](http://www.ncbi.nlm.nih.gov/pubmed/1988710)

[parenchymal malignancies with vena caval thrombus.](http://www.ncbi.nlm.nih.gov/pubmed/1988710) J Urol. 1991 Feb;145(2):243-7.

1. **Koch MO**, McDougal WS, Reddy PK, Lange PH: [Metabolic alterations following continent urinary](http://www.ncbi.nlm.nih.gov/pubmed/1988717)

[diversion through colonic segments.](http://www.ncbi.nlm.nih.gov/pubmed/1988717) J Urol. 1991 Feb;145(2):270-3.

1. Stewart JR, Carey JA, McDougal WS, Merrill WH, **Koch MO**, Bender HW Jr.: [Cavoatrial tumor](http://www.ncbi.nlm.nih.gov/pubmed/1850976)

[thrombectomy using cardiopulmonary bypass without circulatory arrest.](http://www.ncbi.nlm.nih.gov/pubmed/1850976) Ann Thorac Surg. 1991 May;51(5):717-21; discussion 721-2.

1. **Koch MO**, McDougal WS, Flora MD: [Urease and the acidosis of urinary intestinal diversion.](http://www.ncbi.nlm.nih.gov/pubmed/1856952) J Urol. 1991

Aug;146(2):458-62.

1. **Koch MO**: [Therasonics lithotripsy system.](http://www.ncbi.nlm.nih.gov/pubmed/1754768) Semin Urol. 1991 Nov;9(4):275-8.
2. **Koch MO**, McDougal WS, Thompson CO: [Mechanisms of solute transport following urinary diversion](http://www.ncbi.nlm.nih.gov/pubmed/1942308)

[through intestinal segments: an experimental study with rats.](http://www.ncbi.nlm.nih.gov/pubmed/1942308) J Urol. 1991 Nov;146(5):1390-4.

1. Hall MC, **Koch MO**, McDougal WS: [Metabolic consequences of urinary diversion through](http://www.ncbi.nlm.nih.gov/pubmed/1949404)

[intestinal segments.](http://www.ncbi.nlm.nih.gov/pubmed/1949404)Urol Clin North Am. 1991 Nov;18(4):725-35.

1. Follis HW, **Koch MO**, McDougal WS: [Immediate management of prostatomembranous urethral](http://www.ncbi.nlm.nih.gov/pubmed/1569663)

[disruptions.](http://www.ncbi.nlm.nih.gov/pubmed/1569663) J Urol. 1992 May;147(5):1259-62.

1. **Koch MO**, McDougal WS, Hall MC, Hill DE, Braren HV, Donofrio MN: [Long-term metabolic effects of](http://www.ncbi.nlm.nih.gov/pubmed/1569680)

[urinary diversion: a comparison of myelomeningocele patients managed by clean intermittent catheterization and urinary diversion.](http://www.ncbi.nlm.nih.gov/pubmed/1569680) J Urol. 1992 May;147(5):1343-7.

1. Fisher RE, **Koch MO**: [Recognition and management of delayed disruption vesicourethral anastomosis in](http://www.ncbi.nlm.nih.gov/pubmed/1593690)

[radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/1593690) J Urol. 1992 Jun;147(6):1579-81.

1. Hall MC, **Koch MO**, McDougal W: [Mechanism of ammonium transport by intestinal segments following](http://www.ncbi.nlm.nih.gov/pubmed/1635156)

[urinary diversion: evidence for ionized NH4+ transport via K(+)-pathways.](http://www.ncbi.nlm.nih.gov/pubmed/1635156) J Urol. 1992 Aug;148(2 Pt 1):453-7.

1. **Koch MO**, Hall MC: [Mechanism of ammonium transport: inhibition by potassium and barium.](http://www.ncbi.nlm.nih.gov/pubmed/1404661) J Urol.

1992 Oct;148(4):1285-7

1. **Koch MO**, Coussens D: [Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in](http://www.ncbi.nlm.nih.gov/pubmed/8465122)

[patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.](http://www.ncbi.nlm.nih.gov/pubmed/8465122) Semin Urol. 1993 Feb;11(1):14-9.

1. Hall MC, **Koch MO**, Halter SA, Dahlstedt SM: [Morphologic and functional alterations of intestinal](http://www.ncbi.nlm.nih.gov/pubmed/8437284)

[segments following urinary diversion.](http://www.ncbi.nlm.nih.gov/pubmed/8437284) J Urol. 1993 Mar;149(3):664-6.

1. Jones JS, **Koch MO**: [Delayed rupture of type I posterior urethral injury: case report.](http://www.ncbi.nlm.nih.gov/pubmed/8483231) J Urol. 1993

May;149(5):1132-4.

1. **Koch MO**, Coussens DM: [Retrospective analysis of outcome in patients with nodal metastases from](http://www.ncbi.nlm.nih.gov/pubmed/8134985)

[transitional cell carcinoma of lower urinary tract.](http://www.ncbi.nlm.nih.gov/pubmed/8134985) Urology. 1994 Mar;43(3):317-23.

1. Superdock KR, Dummer JS, **Koch MO**, Gilliam DM, Van Buren DH, Nylander WA, Richie RE,

MacDonell RC Jr, Johnson HK, Helderman JH: [Disseminated histoplasmosis presenting as urinary tract obstruction in a renal transplant recipient.](http://www.ncbi.nlm.nih.gov/pubmed/8154500) Am J Kidney Dis. 1994 Apr;23(4):600-4.

1. Scaletscky R, **Koch MO**, Eckstein CW, Bicknell SL, Gray GF Jr, Smith JA Jr.: [Tumor volume](http://www.ncbi.nlm.nih.gov/pubmed/7515448)

[and stage in carcinoma of the prostate detected by elevations in prostate specific antigen.](http://www.ncbi.nlm.nih.gov/pubmed/7515448) J Urol. 1994 Jul;152(1):129-31.

1. **Koch MO**, Coussens D, Burnett L: [The ovarian remnant syndrome and ureteral obstruction: medical](http://www.ncbi.nlm.nih.gov/pubmed/8201651)

[management.](http://www.ncbi.nlm.nih.gov/pubmed/8201651) J Urol. 1994 Jul;152(1):158-60.

1. Robertson JB, **Koch MO**, Kirchner FK Jr, Smith JA Jr.: [Suboptimal treatment results with the Therasonics](http://www.ncbi.nlm.nih.gov/pubmed/8015060)

[lithotriptor.](http://www.ncbi.nlm.nih.gov/pubmed/8015060) J Urol. 1994 Aug;152(2 Pt 1):317-9.

1. Brandell RA, Hall MC, **Koch MO**, Braren HV: [Exposure of intestinal segments to hemiacidrin: analysis of](http://www.ncbi.nlm.nih.gov/pubmed/8022005)

[metabolic and histological effects using a rat model.](http://www.ncbi.nlm.nih.gov/pubmed/8022005) J Urol. 1994 Aug;152(2 Pt 2):725-7; discussion 728-9.

1. **Koch MO**, Smith JA Jr, Hodge EM, Brandell RA: [Prospective development of a cost-efficient program for](http://www.ncbi.nlm.nih.gov/pubmed/8073545)

[radical retropubic prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/8073545) Urology. 1994 Sep;44(3):311-8.

1. Brandell RA, Scaletscky R, **Koch MO**: [Urinary solute transport by gastric mucosa: a comparison](http://www.ncbi.nlm.nih.gov/pubmed/8073550)

[with ileum using a rat model.](http://www.ncbi.nlm.nih.gov/pubmed/8073550) Urology. 1994 Sep;44(3):343-7.

1. Pope JC, **Koch MO**, Bluth RF: [Renal cell carcinoma in patients with end-stage renal disease: a comparison](http://www.ncbi.nlm.nih.gov/pubmed/7941189)

[of clinical significance in patients receiving hemodialysis and those with renal transplants.](http://www.ncbi.nlm.nih.gov/pubmed/7941189) Urology. 1994 Oct;44(4):497-501.

1. **Koch MO**, Brandell RA, Lin D, Smith JA Jr.: [The effect of sequential compression devices on](http://www.ncbi.nlm.nih.gov/pubmed/8072088)

[intraoperative blood loss during radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/8072088) J Urol. 1994 Oct;152(4):1178-9.

1. **Koch MO**, Smith JA Jr.: L[ocal recurrence of squamous cell carcinoma of the penis.](http://www.ncbi.nlm.nih.gov/pubmed/7974902) Urol Clin North Am.

1994 Nov;21(4):739-43.

1. Hall MC, **Koch MO**, Smith JA Jr.: [Femoral neuropathy complicating urologic abdominopelvic procedures.](http://www.ncbi.nlm.nih.gov/pubmed/7817470)

Urology. 1995 Jan;45(1):146-9.

1. **Koch MO**: [Orthotopic neobladder reconstruction after radical cystectomy.](http://www.ncbi.nlm.nih.gov/pubmed/9118391) Tech Urol. 1995

Winter;1(4):197-203.

1. **Koch MO**: [Primary realignment of prostatomembranous urethral disruptions.](http://www.ncbi.nlm.nih.gov/pubmed/7597351) Semin Urol. 1995

Feb;13(1):38-44.

1. Kotkin L, **Koch MO**: [Morbidity associated with nonoperative management of extraperitoneal bladder](http://www.ncbi.nlm.nih.gov/pubmed/7602631)

[injuries.](http://www.ncbi.nlm.nih.gov/pubmed/7602631) J Trauma. 1995 Jun;38(6):895-8.

1. **Koch MO**, Smith JA Jr.: [Cost containment in urology.](http://www.ncbi.nlm.nih.gov/pubmed/7604475) Urology. 1995 Jul;46(1):14-24; discussion 24-6.
2. **Koch MO**, Smith JA Jr.: [Clinical outcomes associated with the implementation of a cost-efficient](http://www.ncbi.nlm.nih.gov/pubmed/7648063)

[programme for radical retropubic prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/7648063) Br J Urol. 1995 Jul;76(1):28-33.

1. **Koch MO**: [Cost-efficient radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/8521133) Semin Urol Oncol. 1995 Aug;13(3):197-203.
2. **Koch MO**, Seckin B, Smith JA Jr.: [Impact of a collaborative care approach to radical cystectomy and](http://www.ncbi.nlm.nih.gov/pubmed/7637110)

[urinary reconstruction.](http://www.ncbi.nlm.nih.gov/pubmed/7637110) J Urol. 1995 Sep;154(3):996-1001.

1. Kotkin L, **Koch MO**: [Impotence and incontinence after immediate realignment of posterior urethral](http://www.ncbi.nlm.nih.gov/pubmed/8627832)

[trauma: result of injury or management?](http://www.ncbi.nlm.nih.gov/pubmed/8627832) J Urol. 1996 May;155(5):1600-3.

1. **Koch MO**, Smith JA Jr.: [Influence of patient age and co-morbidity on outcome of a collaborative care](http://www.ncbi.nlm.nih.gov/pubmed/8627853)

[pathway after radical prostatectomy and cystoprostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/8627853) J Urol. 1996 May;155(5):1681-4.

1. Pope J, **Koch MO**: [Ureteral replacement with reconfigured colon substitute.](http://www.ncbi.nlm.nih.gov/pubmed/8627855) J Urol. 1996

May;155(5):1693-5.

1. Sarosdy MF, Pisters LL, Carroll PR, Benson MC, Moon TD, Lamm DL, Hudson MA, Lerner SP, **Koch**

**MO**, Schellhammer PF: [Bropirimine immunotherapy of upper urinary tract carcinoma in situ.](http://www.ncbi.nlm.nih.gov/pubmed/8693647) Urology. 1996 Jul;48(1):28-32.

1. **Koch MO**, Smith JA Jr.: [Blood loss during radical retropubic prostatectomy: is preoperative autologous](http://www.ncbi.nlm.nih.gov/pubmed/8709311)

[blood donation indicated?](http://www.ncbi.nlm.nih.gov/pubmed/8709311) J Urol. 1996 Sep;156(3):1077-9; discussion 1079-80.

1. **Koch MO**, Smith JA: [Same day surgery for radical retropubic prostatectomy: is it an attainable goal?](http://www.ncbi.nlm.nih.gov/pubmed/8886081)

Urology. 1996 Oct;48(4):660-1.

1. Chang SS, **Koch MO**: [The use of an extended spiral bladder flap for treatment of upper ureteral loss.](http://www.ncbi.nlm.nih.gov/pubmed/8911370) J

Urol. 1996 Dec;156(6):1981-3.

1. Smith Jr JA, **Koch MO**: [Radical prostatectomy: balancing cost and patient care.](http://www.ncbi.nlm.nih.gov/pubmed/12735832) Can J Urol. 1997 Jun;4(2

Supp 1):34-38.

1. **Koch MO**, Miller DA, Butler R, Lebos L, Collings D, Smith JA Jr.: [Are we selecting the right patients for](http://www.ncbi.nlm.nih.gov/pubmed/9495697)

[treatment of localized prostate cancer? Results of an actuarial analysis.](http://www.ncbi.nlm.nih.gov/pubmed/9495697) Urology. 1998 Feb;51(2):197-202.

1. **Koch MO**: [Cost-effective strategies for the follow-up of patients with germ cell tumors.](http://www.ncbi.nlm.nih.gov/pubmed/9728219) Urol Clin North

Am. 1998 Aug;25(3):495-502.

1. Franke JJ, Gilbert WB, Grier J, **Koch MO**, Shyr Y, Smith JA Jr.: [Early post-prostatectomy pelvic floor](http://www.ncbi.nlm.nih.gov/pubmed/10604344)

[biofeedback.](http://www.ncbi.nlm.nih.gov/pubmed/10604344) J Urol. 2000 Jan;163(1):191-3.

1. Chang SS, **Koch MO**: [The metabolic complications of urinary diversion.](http://www.ncbi.nlm.nih.gov/pubmed/21227290) Urol Oncol. 2000 Mar

Apr;5(2):60-70.

1. **Koch MO**: Management of the dorsal vein complex during radical retropubic prostatectomy. Semin Urol

Oncol. 2000 Feb;18(1):33-7.

1. Parekh DJ, Gilbert WB, **Koch MO**, Smith JA Jr.: [Continent urinary reconstruction versus ileal conduit: a](http://www.ncbi.nlm.nih.gov/pubmed/10840090)

[contemporary single-institution comparison of perioperative morbidity and mortality.](http://www.ncbi.nlm.nih.gov/pubmed/10840090) Urology. 2000 Jun;55(6):852-5.

1. Kömhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, **Koch MO**, Shappell SB, Breyer MD:

[Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas.](http://www.ncbi.nlm.nih.gov/pubmed/10880372) Am J Pathol. 2000 Jul;157(1):29-35.

1. **Koch MO**, Foster RS, Bell B, Beck S, Cheng L, Parekh D, Jung SH: C[haracterization and predictors of](http://www.ncbi.nlm.nih.gov/pubmed/10953139)

[prostate specific antigen progression rates after radical retropubic prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/10953139) J Urol. 2000 Sep;164(3 Pt 1):749-53.

1. **Koch MO**: [Predicting outcomes after radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/11025713) J Urol. 2000 Nov;164(5):1601.
2. Beck SD, Foster RS, Bihrle R, **Koch MO**, Wahle GR, Donohue JP: [Aortic replacement during post](http://www.ncbi.nlm.nih.gov/pubmed/11342909)

[chemotherapy retroperitoneal lymph node dissection.](http://www.ncbi.nlm.nih.gov/pubmed/11342909) J Urol. 2001 May;165(5):1517-20.

1. Jiang J, Ulbright TM, Younger C, Sanchez K, Bostwick DG, **Koch MO**, Eble JN, Cheng L: [Cytokeratin 7](http://www.ncbi.nlm.nih.gov/pubmed/11419977)

[and cytokeratin 20 in primary urinary bladder carcinoma and matched lymph node metastasis.](http://www.ncbi.nlm.nih.gov/pubmed/11419977) Arch Pathol Lab Med. 2001 Jul;125(7):921-3.

1. Beck SD, **Koch MO**: [Spiral ileal neobladder substitution with orthotopic ureteral reimplantation: early](http://www.ncbi.nlm.nih.gov/pubmed/11575519)

[results.](http://www.ncbi.nlm.nih.gov/pubmed/11575519) Tech Urol. 2001 Sep;7(3):223-8.

1. Cheng L, Gu J, Eble JN, Bostwick DG, Younger C, MacLennan GT, Abdul-Karim FW, Geary WA, **Koch**

**MO**, Zhang S, Ulbright TM: [Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas.](http://www.ncbi.nlm.nih.gov/pubmed/11688456) Am J Surg Pathol. 2001 Oct;25(10):1231-6.

1. Soergel TM, **Koch MO**, Foster RS, Bihrle R, Wahle G, Gardner T, Jung SH: [Accuracy of predicting long](http://www.ncbi.nlm.nih.gov/pubmed/11696735)

[term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/11696735) J Urol. 2001 Dec;166(6):2198-201.

1. Cheng L, Gu J, Ulbright TM, MacLennan GT, Sweeney CJ, Zhang S, Sanchez K, **Koch MO**, Eble JN:

[Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor.](http://www.ncbi.nlm.nih.gov/pubmed/11815965) Cancer. 2002 Jan 1;94(1):104-10.

1. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, Zhang S, Eckert GJ, **Koch MO**, Eble

JN, Cheng L: [Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/11839587) Am J Pathol. 2002 Feb;160(2):667-71.

1. Uchida T, Sanghvi NT, Gardner TA, **Koch MO**, Ishii D, Minei S, Satoh T, Hyodo T, Irie A, Baba S:

[Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report.](http://www.ncbi.nlm.nih.gov/pubmed/11880077) Urology. 2002 Mar;59(3):394-8; discussion 398-9.

1. Shalhav AL, Dabagia MD, Wagner TT, **Koch MO**, Lingeman JE: [Training postgraduate urologists in](http://www.ncbi.nlm.nih.gov/pubmed/11956463)

[laparoscopic surgery: the current challenge.](http://www.ncbi.nlm.nih.gov/pubmed/11956463) J Urol. 2002 May;167(5):2135-7.

1. Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, **Koch MO**, Eble JN, Cheng L: [Fas and Fas](http://www.ncbi.nlm.nih.gov/pubmed/12124829)

[ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/12124829) Cancer. 2002 Jul 15;95(2):296-300.

1. Siqueira TM Jr, Kuo RL, Gardner TA, Paterson RF, Stevens LH, Lingeman JE, **Koch MO**, Shalhav AL:

[Major complications in 213 laparoscopic nephrectomy cases: the Indianapolis experience.](http://www.ncbi.nlm.nih.gov/pubmed/12352393) J Urol. 2002 Oct;168(4 Pt 1):1361-5.

1. Beck SD, Foster RS, Bihrle R, Ulbright T, **Koch MO**, Wahle GR, Einhorn LH, Donohue JP: [Teratoma in](http://www.ncbi.nlm.nih.gov/pubmed/12352402)

[the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.](http://www.ncbi.nlm.nih.gov/pubmed/12352402) J Urol. 2002 Oct;168(4 Pt 1):1402-4.

1. Sanchez KM, Sweeney CJ, Mass R, **Koch MO**, Eckert GJ, Geary WA, Baldridge LA, Zhang S, Eble JN,

Cheng L: [Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.](http://www.ncbi.nlm.nih.gov/pubmed/12365012) Cancer. 2002 Oct 15;95(8):1650-5.

1. **Koch MO**, Jr JS: [Low molecular weight heparin and radical prostatectomy: a prospective analysis of safety](http://www.ncbi.nlm.nih.gov/pubmed/12496924)

[and side effects.](http://www.ncbi.nlm.nih.gov/pubmed/12496924) Prostate Cancer Prostatic Dis. 1997 Dec;1(2):101-104.

1. Fouts RL, Sandusky GE, Zhang S, Eckert GJ, **Koch MO**, Ulbright TM, Eble JN, Cheng L: [Down](http://www.ncbi.nlm.nih.gov/pubmed/12627509)

[regulation of fragile histidine triad expression in prostate carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/12627509) Cancer. 2003 Mar 15;97(6):1447-52.

1. Hong H, **Koch MO**, Foster RS, Bihrle R, Gardner TA, Fyffe J, Ulbright TM, Eble JN, Cheng L: [Anatomic](http://www.ncbi.nlm.nih.gov/pubmed/12655520)

[distribution of periprostatic adipose tissue: a mapping study of 100 radical prostatectomy specimens.](http://www.ncbi.nlm.nih.gov/pubmed/12655520) Cancer. 2003 Apr 1;97(7):1639-43.

1. **Koch MO**, Nayee AH, Sloan J, Gardner T, Wahle GR, Bihrle R, Foster RS: [Early catheter removal after](http://www.ncbi.nlm.nih.gov/pubmed/12771741)

[radical retropubic prostatectomy: long-term followup.](http://www.ncbi.nlm.nih.gov/pubmed/12771741) J Urol. 2003 Jun;169(6):2170-2.

1. Brandli DW, **Koch MO**, Foster RS, Bihrle R, Gardner TA: [Biochemical disease-free survival in patients](http://www.ncbi.nlm.nih.gov/pubmed/12823376)

[with a high prostate-specific antigen level (20-100 ng/mL) and clinically localized prostate cancer after radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/12823376) BJU Int. 2003 Jul;92(1):19-22; discussion 22-3.

1. Mosharafa AA, Foster RS, Bihrle R, **Koch MO**, Ulbright TM, Einhorn LH, Donohue JP: [Does](http://www.ncbi.nlm.nih.gov/pubmed/12910519)

[retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors?](http://www.ncbi.nlm.nih.gov/pubmed/12910519) Cancer. 2003 Aug 15;98(4):753-7.

1. Eichelberger LE, **Koch MO**, Daggy JK, Ulbright TM, Eble JN, Cheng L: [Predicting tumor volume in](http://www.ncbi.nlm.nih.gov/pubmed/14502802)

[radical prostatectomy specimens from patients with prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/14502802) Am J Clin Pathol. 2003 Sep;120(3):386-91.

1. Paterson RF, Ulbright TM, MacLennan GT, Zhang S, Pan CX, Sweeney CJ, Moore CR, Foster RS, **Koch**

**MO**, Eble JN, Cheng L: [Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/14584063) Cancer. 2003 Nov 1;98(9):1830-6.

1. Zeng G, Hu Z, Kinch MS, Pan CX, Flockhart DA, Kao C, Gardner TA, Zhang S, Li L, Baldridge LA,

**Koch MO**, Ulbright TM, Eble JN, Cheng L: [High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia.](http://www.ncbi.nlm.nih.gov/pubmed/14633601) Am J Pathol. 2003 Dec;163(6):2271-6.

1. Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S,

Baldridge LA, Jones TD, **Koch MO**, Ulbright TM, Eble JN, Cheng L: [PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/14977833) Clin Cancer Res. 2004 Feb 15;10(4):1333-7.

1. Mosharafa AA, Foster RS, **Koch MO**, Bihrle R, Donohue JP: [Complications of post-chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/15076289)

[retroperitoneal lymph node dissection for testis cancer.](http://www.ncbi.nlm.nih.gov/pubmed/15076289) J Urol. 2004 May;171(5):1839-41.

1. Cheng L, Pan CX, Zhang JT, Zhang S, Kinch MS, Li L, Baldridge LA, Wade C, Hu Z, **Koch MO**, Ulbright

TM, Eble JN: [Loss of 14-3-3sigma in prostate cancer and its precursors.](http://www.ncbi.nlm.nih.gov/pubmed/15131044) Clin Cancer Res. 2004 May 1;10(9):3064-8.

1. Arora R, **Koch MO**, Eble JN, Ulbright TM, Li L, Cheng L: [Heterogeneity of Gleason grade in multifocal](http://www.ncbi.nlm.nih.gov/pubmed/15160339)

[adenocarcinoma of the prostate.](http://www.ncbi.nlm.nih.gov/pubmed/15160339) Cancer. 2004 Jun 1;100(11):2362-6.

1. Hong H, Kao C, Jeng MH, Eble JN, **Koch MO**, Gardner TA, Zhang S, Li L, Pan CX, Hu Z, MacLennan

GT, Cheng L: [Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status.](http://www.ncbi.nlm.nih.gov/pubmed/15221992) Cancer. 2004 Jul 1;101(1):83-9.

1. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, **Koch MO**: Laser capture microdissection analysis

reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer. 2004 Jul 1;101(1):183-8.

1. Cheng L, Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Lin H, Kuzel TM, Papavero V, Tretiakova

M, Nigro K, **Koch MO**, Eble JN: [Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients.](http://www.ncbi.nlm.nih.gov/pubmed/15329903) Cancer. 2004 Sep 1;101(5):957-62.

1. Soergel TM, Cain MP, Misseri R, Gardner TA, **Koch MO**, Rink RC: [Transitional cell carcinoma of the](http://www.ncbi.nlm.nih.gov/pubmed/15371782)

[bladder following augmentation cystoplasty for the neuropathic bladder.](http://www.ncbi.nlm.nih.gov/pubmed/15371782) J Urol. 2004 Oct;172(4 Pt 2):1649-51; discussion 1651-2.

1. Poulos CK, **Koch MO**, Eble JN, Daggy JK, Cheng L: [Bladder neck invasion is an independent predictor of](http://www.ncbi.nlm.nih.gov/pubmed/15378493)

[prostate-specific antigen recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/15378493) Cancer. 2004 Oct 1;101(7):1563-8.

1. Pan CX, Yang XJ, Lopez-Beltran A, MacLennan GT, Eble JN, Koch MO, Jones TD, Lin H, Nigro K,

Papavero V, Tretiakova M, Cheng L: [c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications.](http://www.ncbi.nlm.nih.gov/pubmed/15502806) Mod Pathol. 2005 Mar;18(3):320-3.

1. Ng JC, **Koch MO**, Daggy JK, Cheng L: [Perineural invasion in radical prostatectomy specimens: lack of](http://www.ncbi.nlm.nih.gov/pubmed/15538241)

[prognostic significance.](http://www.ncbi.nlm.nih.gov/pubmed/15538241) J Urol. 2004 Dec;172(6 Pt 1):2249-51.

1. Sundaram CP, **Koch MO**, Gardner T, Bernie JE: [Utility of the fourth arm to facilitate robot-assisted](http://www.ncbi.nlm.nih.gov/pubmed/15638920)

[laparoscopic radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/15638920) BJU Int. 2005 Jan;95(1):183-6.

1. Emerson RE, **Koch MO**, Daggy JK, Cheng L: [Closest distance between tumor and resection margin in](http://www.ncbi.nlm.nih.gov/pubmed/15644780)

[radical prostatectomy specimens: lack of prognostic significance.](http://www.ncbi.nlm.nih.gov/pubmed/15644780) Am J Surg Pathol. 2005 Feb;29(2):225-9.

1. Eichelberger LE, **Koch MO**, Eble JN, Ulbright TM, Juliar BE, Cheng L: [Maximum tumor diameter is an](http://www.ncbi.nlm.nih.gov/pubmed/15803186)

[independent predictor of prostate-specific antigen recurrence in prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/15803186) Mod Pathol. 2005 Jul;18(7):886-90.

1. Cheng L, Jones TD, McCarthy RP, Eble JN, Wang M, MacLennan GT, Lopez-Beltran A, Yang XJ, **Koch**

**MO**, Zhang S, Pan CX, Baldridge LA: [Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/15855652) Am J Pathol. 2005 May;166(5):1533-9.

1. Cheng L, **Koch MO**, Juliar BE, Daggy JK, Foster RS, Bihrle R, Gardner TA: [The combined percentage of](http://www.ncbi.nlm.nih.gov/pubmed/15860849)

[Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/15860849) J Clin Oncol. 2005 May 1;23(13):2911-7.

1. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, **Koch MO**: [Anatomic distribution and pathologic](http://www.ncbi.nlm.nih.gov/pubmed/15861213)

[characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.](http://www.ncbi.nlm.nih.gov/pubmed/15861213) Mod Pathol. 2005 Aug;18(8):1022-6.

1. Kernek KM, **Koch MO**, Daggy JK, Juliar BE, Cheng L: [The presence of benign prostatic glandular tissue](http://www.ncbi.nlm.nih.gov/pubmed/15976340)

[at surgical margins does not predict PSA recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/15976340) J Clin Pathol. 2005 Jul;58(7):725-8.

1. Cheng L, Poulos CK, Pan CX, Jones TD, Daggy JK, Eble JN, **Koch MO**: [Preoperative prediction of small](http://www.ncbi.nlm.nih.gov/pubmed/16093983)

[volume cancer (less than 0.5 ml) in radical prostatectomy specimens.](http://www.ncbi.nlm.nih.gov/pubmed/16093983) J Urol. 2005 Sep;174(3):898-902.

1. **Koch MO**, Gardner TA: [Thermal-based treatment options for localized prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/16107241) Curr Treat Options

Oncol. 2005 Sep;6(5):379-87.

1. Armatys SA, **Koch MO**, Bihrle R, Gardner TA, Cheng L: [Is it necessary to separate clinical stage T1c](http://www.ncbi.nlm.nih.gov/pubmed/16153198)

[from T2 prostate adenocarcinoma?](http://www.ncbi.nlm.nih.gov/pubmed/16153198) BJU Int. 2005 Oct;96(6):777-80.

1. Wang X, Jones TD, Maclennan GT, Yang XJ, Lopez-Beltran A, Eble JN, **Koch MO**, Lin H, Baldridge LA,

Tretiakova M, Cheng L: [P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.](http://www.ncbi.nlm.nih.gov/pubmed/16158936) Anticancer Res. 2005 May-Jun;25(3B):2001-4.

1. Emerson RE, **Koch MO**, Jones TD, Daggy JK, Juliar BE, Cheng L: [The influence of extent of surgical](http://www.ncbi.nlm.nih.gov/pubmed/16189146)

[margin positivity on prostate specific antigen recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/16189146) J Clin Pathol. 2005 Oct;58(10):1028-32.

1. Dussinger AM, Beck SD, Cheng L, **Koch MO**: [Does wide primary perirectal dissection during radical](http://www.ncbi.nlm.nih.gov/pubmed/16194713)

[retropubic prostatectomy alter pathologic and biochemical outcomes?](http://www.ncbi.nlm.nih.gov/pubmed/16194713) Urology. 2005 Nov;66(5 Suppl):95-100.

1. Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, **Koch MO**: [Lymphovascular invasion is an](http://www.ncbi.nlm.nih.gov/pubmed/16280760)

[independent prognostic factor in prostatic adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/16280760) J Urol. 2005 Dec;174(6):2181-5.

1. Jones TD, **Koch MO**, Lin H, Cheng L: [Visual estimation of tumour extent is not an independent predictor](http://www.ncbi.nlm.nih.gov/pubmed/16287440)

[of prostate specific antigen recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/16287440) BJU Int. 2005 Dec;96(9):1253-7.

1. Gardner TA, **Koch MO**: [Prostate cancer therapy with high-intensity focused ultrasound.](http://www.ncbi.nlm.nih.gov/pubmed/16425987) Clin Genitourin

Cancer. 2005 Dec;4(3):187-92.

1. Jones TD, **Koch MO**, Bunde PJ, Cheng L: [Is prostate-specific antigen (PSA) density better than the](http://www.ncbi.nlm.nih.gov/pubmed/16469012)

[preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy?](http://www.ncbi.nlm.nih.gov/pubmed/16469012) BJU Int. 2006 Mar;97(3):480-4.

1. Hattab EM, **Koch MO**, Eble JN, Lin H, Cheng L: [Tertiary Gleason pattern 5 is a powerful predictor of](http://www.ncbi.nlm.nih.gov/pubmed/16600733)

[biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/16600733) J Urol. 2006 May;175(5):1695-9; discussion 1699.

1. Sung MT, Lin H, **Koch MO**, Davidson DD, Cheng L: [Radial distance of extraprostatic extension measured](http://www.ncbi.nlm.nih.gov/pubmed/17255778)

[by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/17255778) Am J Surg Pathol. 2007 Feb;31(2):311-8.

1. Kerfoot BP, Baker HE, **Koch MO**, Connelly D, Joseph DB, Ritchey ML: [Randomized, controlled trial of](http://www.ncbi.nlm.nih.gov/pubmed/17382760)

[spaced education to urology residents in the United States and Canada.](http://www.ncbi.nlm.nih.gov/pubmed/17382760) J Urol. 2007 Apr;177(4):1481-7.

1. Marks RA, **Koch MO**, Lopez-Beltran A, Montironi R, Juliar BE, Cheng L: [The relationship between the](http://www.ncbi.nlm.nih.gov/pubmed/17490720)

[extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.](http://www.ncbi.nlm.nih.gov/pubmed/17490720) Hum Pathol. 2007 Aug;38(8):1207-11. Epub 2007 May 8.

1. Marks RA, Lin H, **Koch MO**, Cheng L: [Positive-block ratio in radical prostatectomy specimens is an](http://www.ncbi.nlm.nih.gov/pubmed/17527074)

[independent predictor of prostate-specific antigen recurrence.](http://www.ncbi.nlm.nih.gov/pubmed/17527074) Am J Surg Pathol. 2007 Jun;31(6):877-81.

1. Cheng L, Davidson DD, Lin H, **Koch MO**: [Percentage of Gleason pattern 4 and 5 predicts survival after](http://www.ncbi.nlm.nih.gov/pubmed/17823907)

[radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/17823907) Cancer. 2007 Nov 1;110(9):1967-72.

1. **Koch MO**, Gardner T, Cheng L, Fedewa RJ, Seip R, Sanghvi NT: [Phase I/II trial of high intensity focused](http://www.ncbi.nlm.nih.gov/pubmed/17936800)

[ultrasound for the treatment of previously untreated localized prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/17936800) J Urol. 2007 Dec;178(6):2366-70; discussion 2370-1. Epub 2007 Oct 22. Erratum in: J Urol. 2008 Jan;179(1):386. Sangvhi, Narendra T [corrected to Sanghvi, Narendra T].

1. **Koch MO**: [Positive margins in urological oncology.](http://www.ncbi.nlm.nih.gov/pubmed/17936808) J Urol. 2007 Dec;178(6):2249. Epub 2007 Oct 22.
2. Hahn NM, Kelley MR, Klaunig JE, **Koch MO**, Li L, Sweeney CJ: [Constitutional polymorphisms of](http://www.ncbi.nlm.nih.gov/pubmed/18041919)

[prostate cancer: prognostic and diagnostic implications.](http://www.ncbi.nlm.nih.gov/pubmed/18041919) Future Oncol. 2007 Dec;3(6):665-82.

1. **Koch MO**, Sanghvi N: [Re: Editorial comments: C. G. Chaussy and A. Blana, J Urol 2007; 178: 2369-2371.](http://www.ncbi.nlm.nih.gov/pubmed/18082823)

J Urol. 2008 Feb;179(2):789. Epub 2007 Dec 20.

1. **Koch MO**: [Focal prostate therapy.](http://www.ncbi.nlm.nih.gov/pubmed/18423729) J Urol. 2008 Jun;179(6):2091. doi: 10.1016/j.juro.2008.03.035.
2. Armatys SA, Mellon MJ, Beck SD, **Koch MO**, Foster RS, Bihrle R: [Use of ileum as ureteral replacement](http://www.ncbi.nlm.nih.gov/pubmed/19013597)

[in urological reconstruction.](http://www.ncbi.nlm.nih.gov/pubmed/19013597) J Urol. 2009 Jan;181(1):177-81. doi: 10.1016/j.juro.2008.09.019. Epub 2008 Nov 14.

1. Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group: [Challenges in clinical prostate](http://www.ncbi.nlm.nih.gov/pubmed/19457806)

[cancer: role of imaging.](http://www.ncbi.nlm.nih.gov/pubmed/19457806) AJR Am J Roentgenol. 2009 Jun;192(6):1455-70. doi: 10.2214/AJR.09.2579.

1. Cheng L, Zhang S, Davidson DD, MacLennan GT, **Koch MO**, Montironi R, Lopez-Beltran A: [Molecular](http://www.ncbi.nlm.nih.gov/pubmed/19663734)

[determinants of tumor recurrence in the urinary bladder.](http://www.ncbi.nlm.nih.gov/pubmed/19663734) Future Oncol. 2009 Aug;5(6):843-57. doi: 10.2217/fon.09.50.

1. Sung MT, Zhang S, Lopez-Beltran A, Montironi R, Wang M, Davidson DD, **Koch MO**, Cain MP, Rink

RC, Cheng L: [Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations.](http://www.ncbi.nlm.nih.gov/pubmed/19694823) Histopathology. 2009 Aug;55(2):161-73. doi: 10.1111/j.1365-2559.2009.03363.x.

1. Britt LD, Sachdeva AK, Healy GB, Whalen TV, Blair PG; Members of ACS Task Force on Resident Duty

Hours: [Resident duty hours in surgery for ensuring patient safety, providing optimum resident education and training, and promoting resident well-being: a response from the American College of Surgeons to the Report of the Institute of Medicine, "Resident Duty Hours: Enhancing Sleep, Supervision, and Safety".](http://www.ncbi.nlm.nih.gov/pubmed/19715795) Surgery. 2009 Sep;146(3):398-409. doi: 10.1016/j.surg.2009.07.002.

1. Bahler CD, Foster RS, Bihrle R, Beck SD, Gardner TA, Sundaram CP, Masterson TA, Cheng L, **Koch**

**MO**: [Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/19863521) BJU Int. 2010 May;105(10):1372-6. doi: 10.1111/j.1464-410X.2009.08979.x. Epub 2009 Oct 26.

1. Davidson DD, **Koch MO**, Lin H, Jones TD, Biermann K, Cheng L: [Does the size matter?: Prostate weight](http://www.ncbi.nlm.nih.gov/pubmed/20231620)

[does not predict PSA recurrence after radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/20231620) Am J Clin Pathol. 2010 Apr;133(4):662-8. doi: 10.1309/AJCPPHGXDI94SGAC.

1. Cheng L, Davidson DD, Maclennan GT, Williamson SR, Zhang S, **Koch MO**, Montironi R, Lopez-Beltran

A: [The origins of urothelial carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/20553211) Expert Rev Anticancer Ther. 2010 Jun;10(6):865-80. doi: 10.1586/era.10.73.

1. Ehrlich Y, Foster RS, Bihrle R, Cheng L, Tong Y, **Koch MO**: [Division of prostatic anterior fibromuscular](http://www.ncbi.nlm.nih.gov/pubmed/20605194)

[stroma reduces urethral resistance in an ex vivo human prostate model.](http://www.ncbi.nlm.nih.gov/pubmed/20605194) Urology. 2010 Aug;76(2):511.e10-3. doi: 10.1016/j.urology.2010.03.035.

1. **Koch MO**: [Should the patient with positive margins after radical prostatectomy receive adjuvant radiation?](http://www.ncbi.nlm.nih.gov/pubmed/20851435)

J Urol. 2010 Nov;184(5):1838-9. doi: 10.1016/j.juro.2010.08.055. Epub 2010 Sep 18.

1. Dill AL, Eberlin LS, Zheng C, Costa AB, Ifa DR, Cheng L, Masterson TA, **Koch MO**, Vitek O, Cooks

RG: [Multivariate statistical differentiation of renal cell carcinomas based on lipidomic analysis by ambient ionization imaging mass spectrometry.](http://www.ncbi.nlm.nih.gov/pubmed/20953777) Anal Bioanal Chem. 2010 Dec;398(7-8):2969-78. doi: 10.1007/s00216-010-4259-6. Epub 2010 Oct 15.

1. Wang X, Hickey RJ, Malkas LH, **Koch MO**, Li L, Zhang S, Sandusky GE, Grignon DJ, Eble JN, Cheng L:

[Elevated expression of cancer-associated proliferating cell nuclear antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/21031434) Prostate. 2011 May 15;71(7):748-54. doi: 10.1002/pros.21291. Epub 2010 Oct 28.

1. Masterson TA, Cheng L, **Koch MO**: [Pathological characterization of unifocal prostate cancers in whole](http://www.ncbi.nlm.nih.gov/pubmed/21062398)

[mount radical prostatectomy specimens.](http://www.ncbi.nlm.nih.gov/pubmed/21062398) BJU Int. 2011 May;107(10):1587-91. doi: 10.1111/j.1464-410X.2010.09849.x. Epub 2010 Nov 9.

1. Dill AL, Eberlin LS, Costa AB, Zheng C, Ifa DR, Cheng L, Masterson TA, **Koch MO**, Vitek O, Cooks

RG: [Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry.](http://www.ncbi.nlm.nih.gov/pubmed/21284043) Chemistry. 2011 Mar 1;17(10):2897-902. doi: 10.1002/chem.201001692. Epub 2011 Jan 31.

1. Masterson TA, Cheng L, Mehan RM, **Koch MO**: [Tumor focality does not predict biochemical recurrence](http://www.ncbi.nlm.nih.gov/pubmed/21679993)

[after radical prostatectomy in men with clinically localized prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/21679993) J Urol. 2011 Aug;186(2):506-10. doi: 10.1016/j.juro.2011.03.106. Epub 2011 Jun 15.

1. Gardner TA, Tirkes T, Mellon M, **Koch MO**: [Imaging techniques for the patient with renal cell carcinoma.](http://www.ncbi.nlm.nih.gov/pubmed/21784273)

Semin Nephrol. 2011 May;31(3):245-53. doi: 10.1016/j.semnephrol.2011.05.004.

1. Masterson TA, Cheng L, Boris RS, **Koch MO**: [Open vs. robotic-assisted radical prostatectomy: A single](http://www.ncbi.nlm.nih.gov/pubmed/22222059)

[surgeon and pathologist comparison of pathologic and oncologic outcomes.](http://www.ncbi.nlm.nih.gov/pubmed/22222059) Urol Oncol. 2013 Oct;31(7):1043-8. doi: 10.1016/j.urolonc.2011.12.002. Epub 2012 Jan 4.

1. Cary KC, Johnson CS, Cheng L, **Koch MO**: [A critical assessment of post-prostatectomy prostate specific](http://www.ncbi.nlm.nih.gov/pubmed/22425101)

[antigen doubling time acceleration--is it stable?](http://www.ncbi.nlm.nih.gov/pubmed/22425101) J Urol. 2012 May;187(5):1614-9. doi:

10.1016/j.juro.2011.12.069. Epub 2012 Mar 14.

1. Rice KR, **Koch MO**, Cheng L, Masterson TA: [Dyslipidemia, statins and prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/22845413) Expert Rev

Anticancer Ther. 2012 Jul;12(7):981-90. doi: 10.1586/era.12.75.

1. Png KS, **Koch MO**: [Technique of pelvic lymphadenectomy after robot-assisted laparoscopic prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/23075403)

[for prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23075403) J Endourol. 2012 Dec;26(12):1600-4. doi: 10.1089/end.2012.0375. Epub 2012 Oct 17.

1. Rao Q, Williamson SR, Lopez-Beltran A, Montironi R, Huang W, Eble JN, Grignon DJ, **Koch MO**, Idrees MT, Emerson RE, Zhou XJ, Zhang S, Baldridge LA, Cheng L: [Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers.](http://www.ncbi.nlm.nih.gov/pubmed/23348900) Mod Pathol. 2013 May;26(5):725-32. doi: 10.1038/modpathol.2012.229. Epub 2013 Jan 25.
2. Huang W, Williamson SR, Rao Q, Lopez-Beltran A, Montironi R, Eble JN, Grignon DJ, Idrees MT,

Emerson RE, Zhou XJ, Zhang S, Baldridge LA, Hahn NM, Wang M, **Koch MO**, Cheng L: [Novel markers of squamous differentiation in the urinary bladder.](http://www.ncbi.nlm.nih.gov/pubmed/23806524) Hum Pathol. 2013 Oct;44(10):1989-97. doi: 10.1016/j.humpath.2013.04.005. Epub 2013 Jun 24.

1. Alexander RE, Montironi R, Lopez-Beltran A, Williamson SR, Wang M, Post KM, Sen JD, Arnold AK,

Zhang S, Wang X, **Koch MO**, Hahn NM, Masterson TA, Maclennan GT, Davidson DD, Compérat E, Cheng L: [EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.](http://www.ncbi.nlm.nih.gov/pubmed/23887300) Mod Pathol. 2013 Jul 26. doi: 10.1038/modpathol.2013.132.

1. Pedrosa JA, **Koch MO**, Cheng L: [Lymph node-positive bladder cancer: surgical, pathologic, molecular and prognostic aspects.](http://www.ncbi.nlm.nih.gov/pubmed/24134387) Expert Rev Anticancer Ther. 2013 Nov;13(11):1281-95. doi: 10.1586/14737140.2013.850847.
2. Alexander RE, Montironi R, Lopez-Beltran A, Williamson SR, Wang M, Post KM, Sen JD, Arnold AK, Zhang S, Wang X, Koch MO, Hahn NM, Masterson TA, MacLennan GT, Davidson DD, Compérat E, Cheng L.[EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/23887300)Mod Pathol. 2014 Jan;27(1):107-12. doi: 10.1038/modpathol.2013.132. Epub 2013 Jul 26.
3. Liu NW, Hackney JT, Gellhaus PT, Monn MF, Masterson TA, Bihrle R, Gardner TA, House MG, Koch MO. [Incidence and risk factors of parastomal hernia in patients undergoing radical cystectomy and ileal conduit diversion.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24333109) J Urol. 2014 May;191(5):1313-8. doi: 10.1016/j.juro.2013.11.104. Epub 2013 Dec 10. PMID: 24333109
4. Kaimakliotis HZ, Monn MF, Cheng L, Masterson TA, Cary KC, Pedrosa JA, Foster RS, Koch MO, Bihrle R. [Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24582117) Urology. 2014 May;83(5):1112-6. doi: 10.1016/j.urology.2013.12.035. Epub 2014 Feb 26. PMID: 24582117
5. Williamson SR, Wang M, Montironi R, Eble JN, Lopez-Beltran A, Zhang S, Fan R, Wang L, Osunkoya AO, Koch MO, Cheng L. [Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24743222) Mod Pathol. 2014 Nov;27(11):1540-8. doi: 10.1038/modpathol.2014.48. Epub 2014 Apr 18. PMID: 24743222
6. Alexander RE, Williamson SR, Richey J, Lopez-Beltran A, Montironi R, Davidson DD, Idrees MT, Jones CL, Zhang S, Wang L, Rao Q, Pedrosa JA, Kaimakliotis HZ, Monn MF, Koch MO, Cheng L. [The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24752337) PLoS One. 2014 Apr 21;9(4):e95724. doi: 10.1371/journal.pone.0095724. eCollection 2014. PMID: 24752337
7. Monn MF, Jain R, Kaimakliotis HZ, Flack CK, Koch MO, Boris RS. [Examining the relationship between operative time and hospitalization time in minimally invasive and open urologic procedures.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24786698) J Endourol. 2014 Sep;28(9):1132-7. doi: 10.1089/end.2014.0259. Epub 2014 Jun 3. PMID: 24786698
8. Monn MF, Kaimakliotis HZ, Cary KC, Pedrosa JA, Flack CK, Koch MO, Bihrle R. [Short-term morbidity and mortality of Indiana pouch, ileal conduit, and neobladder urinary diversion following radical cystectomy.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24856979) Urol Oncol. 2014 Nov;32(8):1151-7. doi: 10.1016/j.urolonc.2014.04.009. Epub 2014 May 23. PMID: 24856979
9. Monn MF, Cary KC, Kaimakliotis HZ, Flack CK, Koch MO. [National trends in the utilization of robotic-assisted radical cystectomy: an analysis using the Nationwide Inpatient Sample.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24863014) Urol Oncol. 2014 Aug;32(6):785-90. doi: 10.1016/j.urolonc.2014.04.007. Epub 2014 May 23. PMID: 24863014
10. Kaimakliotis HZ, Monn MF, Cary KC, Pedrosa JA, Rice K, Masterson TA, Gardner TA, Hahn NM, Foster RS, Bihrle R, Cheng L, Koch MO. [Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm?](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/24954925) Urol Oncol. 2014 Aug;32(6):833-8. doi: 10.1016/j.urolonc.2014.03.008. Epub 2014 Jun 18.PMID: 24954925
11. Pedrosa JA, Kaimakliotis HZ, Monn MF, Cary KC, Masterson TA, Rice KR, Foster RS, Bihrle R, Koch MO, Cheng L. [Critical analysis of the 2010 TNM classification in patients with lymph node-positive bladder cancer: influence of lymph node disease burden.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25027685) Urol Oncol. 2014 Oct;32(7):1003-9. doi: 10.1016/j.urolonc.2014.04.002. Epub 2014 Jul 11. PMID: 25027685
12. Rice KR, Koch MO, Kao CS, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Bihrle R, Cheng L. [Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25047418) Urol Oncol. 2015 Jan;33(1):20.e23-9. doi: 10.1016/j.urolonc.2014.06.012. Epub 2014 Jul 18. PMID: 25047418
13. Monn MF, Kaimakliotis HZ, Cary KC, Bihrle R, Pedrosa JA, Masterson TA, Foster RS, Gardner TA, Cheng L, Koch MO. [The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity?](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25060358) BJU Int. 2014 Jul 25. doi: 10.1111/bju.12877. [Epub ahead of print] PMID: 25060358
14. Yang DY, Monn MF, Kaimakliotis HZ, Cary KC, Cheng L, Koch MO. [Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25240762) Urol Oncol. 2015 Feb;33(2):70.e9-70.e14. doi: 10.1016/j.urolonc.2014.07.003. Epub 2014 Sep 16. PMID: 25240762
15. Gellhaus PT, Monn MF, Leese J, Flack CK, Lingeman JE, Koch MO, Boris RS. [Robot-Assisted Radical Prostatectomy in Patients with a History of Holmium Laser Enucleation of the Prostate: Feasibility and Evaluation of Initial Outcomes.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25423412) J Endourol. 2014 Nov 25. [Epub ahead of print] PMID: 25423412
16. Koch MO. [Editorial comment.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25443921) Urology. 2014 Nov;84(5):1162. doi: 10.1016/j.urology.2014.06.055. Epub 2014 Oct 24. No abstract available. PMID: 25443921
17. Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, Koch MO. [Contemporary bladder cancer: variant histology may be a significant driver of disease.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25459358) Monn MF, Urol Oncol. 2015 Jan;33(1):18.e15-20. doi: 10.1016/j.urolonc.2014.10.001. Epub 2014 Nov 1. PMID: 25459358
18. Kerian KS, Jarmusch AK, Pirro V, Koch MO, Masterson TA, Cheng L, Cooks RG. [Differentiation of prostate cancer from normal tissue in radical prostatectomy specimens by desorption electrospray ionization and touch spray ionization mass spectrometry.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25521825) Analyst. 2015 Feb 21;140(4):1090-8. doi: 10.1039/c4an02039a. PMID: 25521825
19. Fisher KW, Montironi R, Lopez Beltran A, Moch H, Wang L, Scarpelli M, Williamson SR, Koch MO, Cheng L. [Molecular foundations for personalized therapy in prostate cancer.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25547910) Curr Drug Targets. 2015;16(2):103-14. PMID: 25547910
20. Koch MO. [Editorial comment.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25623698) Urology. 2015 Feb;85(2):392-3. doi: 10.1016/j.urology.2014.08.061. No abstract available. PMID: 25623698
21. Pedrosa JA, Koch MO, Kaimakliotis HZ, Monn MF, Masterson TA, Rice KR, Cary KC, Foster RS, Bihrle R, Cheng L. [Three-tiered nodal classification system for bladder cancer: a new proposal.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25675122) Future Oncol. 2015;11(3):399-408. doi: 10.2217/fon.14.267. PMID: 25675122
22. Shatagopam K, Kaimakliotis HZ, Cheng L, Koch MO. [Genitourinary small cell malignancies: prostate and bladder.](http://www-ncbi-nlm-nih-gov.proxy.medlib.uits.iu.edu/pubmed/25675127) Future Oncol. 2015;11(3):479-88. doi: 10.2217/fon.14.277. PMID: 25675127
23. Pedrosa JA, Masterson TA, Rice KR, Kaimakliotis HZ, Monn MF, Bihrle R, Koch MO, Boris RS. Oncologic outcomes and prognostic impact of urothelial recurrences in patients undergoing segmental and total ureterectomy for upper tract urothelial carcinoma. Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E187-92. doi: 10.5489/cuaj.2408. PMID: 26085878
24. Liu NW, Shatagopam K, Monn MF, Kaimakliotis HZ, Cary C, Boris RS, Mellon MJ, Masterson TA, Foster RS, Gardner TA, Bihrle R, House MG, Koch MO. Risk for Clostridium difficile infection after radical cystectomy for bladder cancer: Analysis of a contemporary series. Urol Oncol. 2015 Dec;33(12):503.e17-22. doi: 10.1016/j.urolonc.2015.07.007. PMID: 26278363
25. Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan;34(1):4.e11-7. doi: 10.1016/j.urolonc.2015.08.005. PMID: 26362343
26. Alexander RE, Wang L, Lopez-Beltran A, Emerson RE, Montironi R, Pedrosa JA, Kaimakliotis HZ, Koch MO, Cheng L. Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link? Histol Histopathol. 2016 Jun;31(6):595-600. doi: 10.14670/HH-11-715. PMID: 26687533
27. Bahler CD, Sundaram CP, Kella N, Lucas SM, Boger MA, Gardner TA, Koch MO. A Parallel Randomized Clinical Trial Examining the Return of Urinary Continence after Robot-Assisted Radical Prostatectomy with or without a Small Intestinal Submucosa Bladder Neck Sling. J Urol. 2016 Jul;196(1):179-84. doi: 10.1016/j.juro.2016.01.010. PMID: 26784645
28. Koch MO. Editorial Comment. J Urol. 2016 May;195(5):1414. doi: 10.1016/j.juro.2015.11.087. No abstract available. PMID: 26852000
29. Koch MO. Robotic versus Open Prostatectomy: End of the Controversy. J Urol. 2016 Jul;196(1):9-10. doi: 10.1016/j.juro.2016.04.047. No abstract available. PMID: 27086181
30. Monn MF, Jaqua KR, Calaway AC, Mellon MJ, Koch MO, Boris RS. Impact of Obesity on Wound Complications Following Radical Prostatectomy Is Mitigated by Robotic Technique. J Endourol. 2016 Aug;30(8):890-5. doi: 10.1089/end.2016.0282. PMID: 27246319
31. Kaimakliotis HZ, Monn MF, Cho JS, Pedrosa JA, Hahn NM, Albany C, Gellhaus PT, Cary KC, Masterson TA, Foster RS, Bihrle R, Cheng L, Koch MO. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. Future Oncol. 2016 Aug;12(15):1795-804. doi: 10.2217/fon-2016-0056. PMID: 27255805
32. Koch MO, Cho JS, Kaimakliotis HZ, Cheng L, Sangale Z, Brawer M, Welbourn W, Reid J, Stone S. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. Cancer Biomark. 2016 Jun 7;17(1):83-8. doi: 10.3233/CBM-160620. PMID: 27314296
33. Koch MO. High Intensity Focused Ultrasound is a Good Treatment Option for Localized Prostate Cancer: Pro. J Urol. 2016 Dec;196(6):1610-1612. doi: 10.1016/j.juro.2016.09.006. No abstract available. PMID: 27638337
34. Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. PMID: 27932416
35. Green MA, Eitel JA, Fletcher JW, Mathias CJ, Tann MA, Gardner T, Koch MO, Territo W, Polson H, Hutchins GD. Estimation of radiation dosimetry for 68Ga-HBED-CC (PSMA-11) in patients with suspected recurrence of prostate cancer. Nucl Med Biol. 2017 Mar;46:32-35. doi: 10.1016/j.nucmedbio.2016.11.002. Epub 2016 Nov 4. PMID: 28012435
36. Thomas DE, Kaimakliotis HZ, Rice KR, Pereira JA, Johnston P, Moore ML, Reed A, Cregar DM, Franklin C, Loman RL, Koch MO, Bihrle R, Foster RS, Masterson TA, Gardner TA, Sundaram CP, Powell CR, Beck SD, Grignon DJ, Cheng L, Albany C, Hahn NM. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy. Clin Genitourin Cancer. 2016 Nov 30. pii: S1558-7673(16)30345-7. doi: 10.1016/j.clgc.2016.11.009. [Epub ahead of print] PMID: 28040424
37. Gellhaus PT, Cary C, Kaimakliotis HZ, Johnson CS, Weiner M, Koch MO, Bihrle R. Long-term Health-related Quality of Life Outcomes Following Radical Cystectomy. Urology. 2017 Apr 26. pii: S0090-4295(17)30392-8. doi: 10.1016/j.urology.2017.03.053. [Epub ahead of print] PMID: 28456541
38. Koch MO. Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU Int. 2017 Jun;119(6):816. doi: 10.1111/bju.13808. No abstract available. PMID: 28544712

**CHAPTERS:**

1. **Koch MO**, McDougal WS: Genitourinary trauma in children. In: Marcus RE (ed). Trauma in Children. Rockville, Maryland: Aspen Publications, Inc., 1986.
2. **Koch MO**, Kirchner FK Jr: Disease of the genitourinary system in the elderly. In: Adkins RB, Scott HW JR (eds). Surgical Care of the Elderly. Baltimore: Williams & Wilkins, 1988, pp. 370-384.
3. **Koch MO**, McDougal WS: Ureter substitution. In: McDougal WS (ed). Difficult Problems in Urologic Surgery. Chicago, Illinois: Yearbook Medical Publishers, 1988, pp. 76-100.
4. **Koch MO**, McDougal WS: The case for primary lymphadenectomy in penile cancer. In: Lepor H (ed). Urologic Oncology IV. Boston: Kluwer Academic Publishers, 1989, pp. 55-64.
5. Watkins SE, **Koch MO**, McDougal WS: Genitourinary trauma. In: Rakel RE (ed). Conn's Current Therapy. Philadelphia, Pennsylvania: WB Saunders Company, 1990.
6. **Koch MO**, McDougal WS: Overview: Management of penile carcinoma. In: Whitehead D (ed). Current Operative Urology. Philadelphia, Pennsylvania: JP Lippincott, 1990.
7. **Koch MO**: Disorders of micturition. In: Jacobson HR, Striker GE, Klahr SK (eds). The Principles and Practice of Nephrology. Philadelphia, Pennsylvania: BC Decker, Inc., 1991, pp. 452-457.
8. **Koch MO**: Genitourinary trauma. In: Rakel RE (ed). Conn's Current Therapy. Philadelphia, Pennsylvania: WB Saunders Company, p. 621-625, 1992.
9. **Koch MO**: Urinary tract reconstruction with intestine. In: Stein, Caldamone, Smith(ed). Practice of Urology. April 1992.
10. **Koch MO**: Urinary diversion. In: Sant (ed). Pathophysiologic Principles in Urology. January 1994.
11. **Koch MO**: Laser therapy for invasive bladder cancer. In: Smith, Stein, Benson (ed). Lasers in Urologic Surgery, Third Edition. January 1994.
12. Follis HW, **Koch MO**, McDougal WS: Immediate management of prostatomembranous urethral disruptions. Yearbook of Urology, Mosby Yearbook, 1993.
13. **Koch MO**, McDougal WS: Primary realignment of traumatic complete prostatomembranous urethral disruption. In: McAninch JW (ed). Traumatic and Reconstructive Urology, Philadelphia: WB Saunders Co, pp. 385-391, 1996.
14. **Koch MO**: Disorders of micturition. Jacobson HR, Striker GE, Klahr S (eds). The Principles and Practice of Nephrology, Second Edition, St. Louis: Mosby Yearbook, pp. 315-321, 1995.
15. Hall MC and **Koch MO**. Perioperative fluid and electrolyte management. In: Geriatric UrologyPD O=Donnell (ed), Little Brown & Co., pp. 69-81, 1994.
16. **Koch MO** and Smith JA, Jr: Natural history and surgical management of superficial bladder cancer stage (Ta/T1/Cis). In: Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS (eds). Comprehensive Textbooks of Genitourinary Oncology, Baltimore, Williams and Williams, pp. 405-415, 1996.
17. **Koch MO** and Smith JA, Jr: Surgical Management of Adrenal Tumors. In: Principles and Practice of Genitourinary Oncology, Raghavan D, Scher HI, Leibel SA, Lange P (eds), J.B. Lippincott, Philadelphia, pp. 993, 1996.
18. **Koch MO** and Smith JA, Jr: Radical Cystectomy in Men. Atlas of the Urologic Clinics of North America, W.B. Saunders Company, Philadelphia, Vol 5(2), October 1997.
19. **Koch MO**: The Incidental Renal Mass. AUA CD ROM Series, Decker Publishing. PMP #2, 1998.
20. **Koch MO**, Roth B: A man with voiding difficulties and back pain. AUA CD ROM Series, PMP #2, 1998.
21. **Koch MO**, Kirchner FK: Endoscopic realignment of prostatomembranous urethral disruptions. Atlas of Urologic Clinics of North America, W.B. Saunders Company, Philadelphia, Vol6(2), October 1998.
22. Beck SDW and **Koch MO**: Pheochromocytoma. 5 Minute Urology Consult, Section 2, Lippincott Williams & Wilkins, Philadelphia, pp. 386-387, 2000.
23. Beck, SDW and **Koch MO**: Transurethral Resection Syndrome. 5 Minute Urology Consult, Section 2, Lippincott Williams & Wilkins, Philadelphia, pp. 542-543, 2000.
24. Yerkes E and **Koch MO**. The Use of Intestine for Urinary Tract Reconstruction: Metabolic Implications and Management. Urology (Brazilian medical publication)(1996)
25. Baumgartner R, Wells N, **Koch MO**: Radical Prostatectomy. Outcomes of Path-based, Collaborative Practice (1997).
26. **Koch MO**, Smith JA, Miller D, Baumgartner B: Perioperative Management of Radical Prostatectomy: the Impact of Critical Care Pathways. Management of Prostate Cancer (In library, 1997/1998)
27. DeMarco, R., and **Koch, MO.**: Metabolic Alterations After Continent Urinary Diversion. AUA Update Series, (2000).
28. **Koch, MO.**: High Intensity Focused Ultrasound Treatment. Prostate Cancer.

**INVITED LECTURES:**

1. The Use of Bowel in Urology, American Urological Association Continuing Medical Education Course, Atlanta, Georgia, 1988.
2. The Case of Early Repair of Prostatomembranous Urethral, Disruptions, American Urological Association Continuing Medical Education Course, Atlanta, Georgia, 1988.
3. Perioperative Care, ACS Continuing Medical Education Course, New Orleans, Louisiana, 1990.
4. Management of Benign Prostatic Conditions/Prostate Cancer, University of Tennessee Continuing Medical Education Course, Chattanooga, Tennessee, 1990.
5. Perioperative Care, American Urological Association Continuing Medical Education Course, Toronto, Canada, 1991.
6. Symposium on Bladder Cancer, American Urological Association, Toronto, Canada, 1993.
7. Metabolic Complication of Urinary Diversion. ACS, San Francisco, California, 1993.
8. Are we doing too Many Radical Prostatectomies? ACS, San Francisco, California, 1993.
9. Medical Staff, Tullahoma Hospital, “Prostate Carcinoma”, Tullahoma, Tennessee, January 1994.
10. Renal Grand Rounds, “Renal Cell Carcinoma”, Vanderbilt University Medical Center, Nashville, Tennessee, February, 1994.
11. Otolaryngology Grand Rounds, “Collaborative Pathways”, Vanderbilt University Medical Center, Nashville, Tennessee, March 1994.
12. Ophthalmology Grand Rounds, “Collaborative Pathways”, Vanderbilt University Medical Center, Nashville, Tennessee, April 1994.
13. American Urological Association Post-Graduate Course on Urologic Oncology, San Antonio, Texas, 1994.
14. Urologic Oncology Course, Atlanta, Georgia, 1994.
15. Medical Staff at Shelbyville Hospital, “Urinary Incontinence in the Elderly: Diagnosis and Treatment”, Shelbyville, Tennessee, April, 1994.
16. Oncology Grand Rounds, “Bladder Cancer”, Vanderbilt University Medical Center, Nashville, Tennessee, June, 1994.
17. Medical Staff, Lebanon Hospital, “Prostate Cancer”, Lebanon, Tennessee, June 1994.
18. Medical Grand Rounds, “Practical Applications of PSA”, Vanderbilt University Medical Center, Nashville, Tennessee, February, 1995.
19. Tennessee Urology Association Annual Meeting, “Cost Containment Strategies in Urology”, Nashville, TN, April, 1995.
20. Medical Staff, Jackson Hospital, “Collaborative Pathways”, Jackson, Tennessee, August, 1995.
21. Birmingham Urology Journal Club, “Care of the Radical Prostatectomy Patient: Facts & Fiction”, Birmingham, Alabama, September, 1995.
22. Surgery Grand Rounds, “The Testicular Mass”, Vanderbilt University Medical Center, Nashville, Tennessee, September, 1995.
23. Twenty-fourth Annual Rhamy-Shelley Visiting Professorship, “Controversies in Urologic Trauma”, Vanderbilt University Medical Center, Nashville, Tennessee, October, 1995.
24. Renal Grand Rounds, “Urinary Tract Reconstruction with Intestine”, Vanderbilt University Medical Center, Nashville, Tennessee, January 1996.
25. Linking Practice Guidelines and Clinical Pathways with Outcome Management, “Radical Retropubic Prostatectomy: A Collaborative Care Pathway Approach to Patient Care”, Sponsored by the University of Medicine and Dentistry and IBC Conferences, Scottsdale, Arizona, February, 1996.
26. Academic Physician Forum on Urology, “Microeconomics of Prostate Cancer for the University Urologist”: Cancun, Mexico, February, 1996.
27. Texas Association of GenitourinarySurgeons, Nashville, Tennessee, April 1996.
28. Medical Staff, Fulton Hospital, Fulton, Kentucky, April, 1996.
29. Tenet Health System, Physician Advisory Board, “Development and Results from a Collaborative Care Program in Urology”, Palm Springs, California, May, 1996.
30. American Urological Association Annual Meeting, “Collaborative Care Pathways”, Orlando, Florida, May 1996.
31. The Upper Cumberland Medical Society’s 102nd Annual Meeting, “Current Treatment of Prostate Cancer”, Fairfield Glade, Tennessee, June 1996.
32. “Current Research in Urologic Cancer”, Bowling Green, Kentucky, September, 1996.
33. Pathology Grand Rounds, “Update on Prostate Cancer”, Vanderbilt University Medical Center, November, 1996.
34. Society of Urologic Oncology Annual Meeting, “New Trials and Recent Results”, New Orleans, Louisiana, April, 1997.
35. American Urological Association Annual Meeting, “Plenary Session on Highlights of Cancer”, New Orleans, Louisiana, April, 1997.
36. Post-Graduate Course, “Perioperative Management of Radical Prostatectomy”, American Urological Association Annual Meeting, New Orleans, Louisiana, April, 1997.
37. Poster Session Moderator, “Management of Localized Prostate Cancer”, American Urological Association Annual Meeting, New Orleans, Louisiana, April, 1997.
38. Trover Foundation, “Critical Pathways”, Hopkinsville, Kentucky, May, 1997.
39. American Cancer Society Urologic Trauma Post-Graduate Course, “Primary Realignment of Prostatomembranous Urethral Disruption Injuries: How I Do It”, Chicago, Illinois, October, 1997.
40. Primary Care Lecture Series, “Prostate Cancer Screening”, Vanderbilt University Medical Center, Nashville, Tennessee, October, 1997.
41. Medical Oncology Division Seminar Series, “The Diagnosis and Treatment of Superficial Bladder Carcinoma”, Vanderbilt University Medical Center, Nashville, Tennessee, October, 1997.
42. 26th Annual Vanderbilt Urology Society Visiting Professorship and Rhamy-Shelley Lecture, “Orthotopic Neobladders in Females”, Vanderbilt University Medical Center, Nashville, Tennessee, November, 1997.
43. The Lance Armstrong Urologic Oncology Meeting, “Radical Prostatectomy: Early and Late Results”, Newport Beach, California, November, 1997.
44. 7th Annual Spring Clinical Nephrology Meeting – Nephrology for the Primary Care Physician Program, “Urologic Problems in the Elderly”, Nashville, Tennessee, March, 1998.
45. Visiting Professor, Ohio State University, June, 1998.
46. Visiting Professor, Northwestern University, 1998.
47. The Lance Armstrong Urologic Oncology Meeting, “Radical Prostatectomy”, Tysons Corner, Virginia, October, 1998.
48. Visiting Professor, University of Michigan, March 1999.
49. Visiting Professor, Montana Urological Society, Bozeman, Montana, September, 1999.
50. National Urology Oncology Update, “Approaches to the Residual Retroperitoneal Mass Post-Chemotherapy”, New York, New York, November, 1999.
51. McDonald Lecturer, Phoenix Urological, November 1999.
52. Practical Update on Urological Oncology, Deer Valley, Utah, January, 2000.
53. Visiting Professor, Southern Illinois University, February, 2000.
54. James H. McDonald Urologic Seminar, Scottsdale, Arizona, March, 2000.
55. “Clinical Problems in Urology”, Northwestern University, Chicago, Illinois, March 2000.
56. University of Michigan, Great Prostate Shootout “For Greater Use of Nerve Sparing Prostatectomy”, Detroit, Michigan, September, 2000.
57. American College of Surgeons, “Colovesical Fistulas”, October, 2000.
58. North Central Section of the American Urological Association, Phoenix “Radical Cystectomy in the Male”, Arizona, November, 2000.
59. Culp Visiting Professor, Iowa Urological Society, September, 2000.
60. Visiting Professor, Albany Medical College, Albany , New York, June 2001
61. Loyola University Visiting Professor, 2003
62. Mayo Clinic Visiting Professor, 2003
63. Clyde Deming Visiting Professor, Yale University Medical School, October 2005
64. Michigan Urologic Invited Speaker, October 2005
65. Jefferson University/Kimmel Cancer Center Visiting Professor, April 2006
66. University of Kansas Visiting Professor, April 2007
67. Henry Ford Medical Center Visiting Professor, June 2008
68. American Urological Association Update Course of Prostate Cancer, San Antonio, October 2008
69. Invited Speaker University of Massachusetts, October 2008
70. Invited Speaker, Michigan Resident’s Day, April 2009
71. Northwestern Ohio Urological Association and University of Toledo College of Medicine Visiting Professor, January 20-21, 2010
72. Southern Illinois University Visiting Professor, Springfield, Illinois, April 2010
73. University of Tennessee Visiting Professor, Memphis, Tennessee, September 2011
74. Union Hospital Visiting Professor, Terre Haute, Indiana, February 2012
75. Invited Speaker, Columbus Hospital Grand Rounds Lecture, Columbus, Indiana, May 2012
76. Invited Speaker, Schneck Medical Center Grand Rounds Lecture, Seymour, Indiana, November 2012
77. Invited Speaker, Ohio State University 2014
78. Invited speaker, Roswell Park Cancer Institute 2014
79. Visiting Professor, Vanderbilt University, 2015.
80. Visiting Professor, University of Tennessee, 2015.

**OTHER RESPONSIBILITIES:**

National Administrative

Reviewer for American Foundation Urologic Disease/National Kidney Foundation Grant Proposals, 1992-1995.

Independent Reviewer, Veterans Administration Merit Review Program.

Member Veterans Administration Merit Review Council, 1994-1995.

Consultant to NIH on RFA on Minimally Invasive Surgery.

Member American Board of Urology/American Urological Association Joint Examination Committee, 1993-1997. Task Force Chairman, 1996-1996.

Member Editorial Board, Patient Management Program Series for American Urological Association, Decker Electronic Publishing, 1996-present.

Chairman of Bylaws Subcommittee, Society of Urologic Oncology, 1996-1998.

Representative from the Southeastern Section of the American Urological Association to the AUA/AFUD Research Committee, 1997-1998.

Examiner for the Oral Examinations for the American Board of Urology, 1998-Present.

Senior Member American Board of Urology Examination Committee, 1999-2003.

Chairman of American Board of Urology Examination Committee, 2000-2004.

Member of Executive Committee, Society of University Urologists.

Member of American Urological Association Education Council American Urological Association.

Representative to American College of Surgeons, Perioperative Care Committee. 1999-2000.

Trustee of American Board of Urology 2004-present (President 2009).

President of Society of University Chairpersons and Program Directors 2005-2006.

President of the Society of University Urologists 2008

Member American Urological Association Core Curriculum Task Force

Vice-Chair, Residency Review Committee for Urology.

Chairman, Residency Review Committee for Urology 2008-2011.

Reviewer for Investigative Section, Journal of Urology.

Reviewer for Journal of Urology.

Reviewer for Urology.

Course Director, Evidence Based Treatment of High Risk Bladder Cancer PG course 2005-2014.

Course Director, How to Build and Successful Department, A Program for Urology Chairman 2009-2015

Secretary of the Clinical Society of Genitourinary Surgeons

Representative for the American Urologic Association on the American Joint Commission on Cancer

Urology Member on International Collaboration on Cancer Reporting, Bladder cancer subgroup, 2015

Regional Administrative

President of the Tennessee Urological Association, 1994-1995.

President Indiana Urological Society.

Member of Executive Committee, North Central Section of American Urological Association, 2001-2005.

Local Administrative

Veterans Administration Credentialing Committee, 1990-1996.

Veterans Administration Research and Development Committee, 1992-1995.

Chairman, Laparoscopy and Laser Ad Hoc Committee, Vanderbilt Hospital, 1991- 1993.

Chief of Urology, Veterans Administration Hospital, 1987-1998.

Admissions Committee Member, Vanderbilt Medical School, 1993-1996.

President of the Vanderbilt Urology Society, 1994.

Chair of the Search Committee for CEO, Indiana University School of Medicine –Specialty Care, Indiana University School of Medicine, 2000.

Member of the Search Committee for Dean, Indiana University School of Medicine 2012

Member of the Robotics Committee, IU Health 2012-present

Chair of Search Committee for Chairman of Department of Surgery, Indiana University School of Medicine, 2001, 2006.

Chair of the Business Affairs Committee Indiana University School of Medicine –Specialty Care, 2001 – 2012

Board member Indiana University Medical Group - Primary Care, 2001-2002.

Chairman of the Board of Faculty Practice Plan, Indiana University School of Medicine, 2001-2008.

Member, Board of Directors for Indiana Clinic. (IU Health), 2011-2012

Service Line Chief Urology, Indiana University Health.

Chair of Department of Surgery Search Committee, Indiana University School of Medicine 2012

Chair of the Department of Orthopedics Search Committee, Indiana University School of Medicine 2015

President of the Council of Clinical Chairs, Indiana University School of Medicine, 2014-2015